PredictCan Biotechnologies
Montpellier / 57 Avenue Théroigne de Méricourt
|
PredictCan Biotechnologies is a new startup that develops innovative tools for early detection of solid cancers and to strengthen anticancer drugs development pipelines. With a long-lasting expertise in translational and personalized medicine, PredictCan Biotechnologies owns a unique technology for a fast and physiologic cellular reprogramming using clinical data from each patient. Combined with AI, this technology allows an early detection of precancerous signatures from a blood sampling, as well as the generation with high-fidelity of a cohort of cancer patients for a new approach of “clinical trials in a dish”. |
|||||||||
| Business axis : |
Diagnostic - Toxicité médicamenteuse - Efficacité thérapeutique pour les molécules anticancéreuses - Essais cliniques in vitro - Modèles dérivés du patient |
||||||||
| Category : | TPE | ||||||||
| Legal form : | SAS | ||||||||
| Number of employees : | 3 | ||||||||
| Website : | |||||||||
| Turnover : |
0.00 K€ |
||||||||